The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Drugmaker Sarepta Therapeutics said late Friday it won't comply with a request from the Food and Drug Administration to halt ...

Sarepta stock has tanked. Most investors don’t see the drugmaker’s executive management as credible following the failure to disclose a patient death, a BMO survey suggests.

Sarepta says it will continue to ship Elevidys despite FDA requests that it stop shipments of the Duchenne muscular dystrophy gene therapy, while Verizon tops earnings expectation and raises 2025 ...

Evotec shares dipped 11.3% to $3.78 in the pre-market trading session. Here are some other stocks moving lower in pre-market trading.

The European Union remains the key wildcard. As the U.S.’s largest trading partner, the EU stands to lose the most from a ...

Investing.com -- Sarepta Therapeutics Inc (NASDAQ: SRPT) stock tumbled 10% following the announcement that the U.S. Food and Drug Administration has placed a clinical hold on the company’s ...

Reducing redundancy and improving hospital compliance are among the goals. Other industry news is on health system purchases of physician practices, insurance claim denials, and more.